Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBPNKT)

• Drug Name: SC-44463 Drug Info
• Synonyms: SC-44463; CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth
• Cross-matching ID:
  PubChem CID: 128564
  CAS Number: CAS 104408-38-0
  TTD Drug ID: DMBPNKT

Molecule-Related Drug Atlas

Drug(s) Targeting Matrix metalloproteinase-8 (MMP-8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CIPEMASTAT	DM803GL	Rheumatoid arthritis	FA20	Phase 3	[4]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[5]
BB-1101	DM7GH5Z	Multiple sclerosis	8A40	Terminated	[6]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[7]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[9]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[10]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	DM37C25	Discovery agent	N.A.	Investigative	[9]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	DM4VADN	Discovery agent	N.A.	Investigative	[9]
Ro-37-9790	DM83QMZ	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Matrix metalloproteinase-1 (MMP-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prinomastat	DM9HOKG	Lung cancer	2C25.0	Approved	[12]
Marimastat	DM6V34C	Pancreatic cancer	2C10	Phase 3	[13]
CIPEMASTAT	DM803GL	Rheumatoid arthritis	FA20	Phase 3	[4]
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[14]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure10(2a)	DMFWXPS	N. A.	N. A.	Patented	[15]
BMS 275291	DMKSFPE	Kaposi sarcoma	2B57	Discontinued in Phase 3	[16]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[17]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[18]
XL784	DMICR39	Diabetic nephropathy	GB61.Z	Discontinued in Phase 2	[19]

Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[20]
DP-b99	DM97S10	Stroke	8B20	Phase 3	[21]
GS-5745	DMP8MDW	Gastric adenocarcinoma	2B72	Phase 3	[22]
Andecaliximab	DMLDB1X	Gastric adenocarcinoma	2B72	Phase 3	[23]
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[24]
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[25]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure17(12)	DMML4PA	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure17(10)	DMVA15O	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-SB-3CT	DMC64XQ	N. A.	N. A.	Patented	[15]

Drug(s) Targeting Matrix metalloproteinase-2 (MMP-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prinomastat	DM9HOKG	Lung cancer	2C25.0	Approved	[12]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[26]
Marimastat	DM6V34C	Pancreatic cancer	2C10	Phase 3	[13]
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[25]
Metastat	DMTQ4PN	Acne vulgaris	ED80	Phase 1	[27]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure10(2a)	DMFWXPS	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure16(9b)	DMPAQLZ	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-SB-3CT	DMC64XQ	N. A.	N. A.	Patented	[15]
PMID29130358-Compound-Figure16(9a)	DMKX5R8	N. A.	N. A.	Patented	[15]

Drug(s) Targeting Matrix metalloproteinase-7 (MMP-7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prinomastat	DM9HOKG	Lung cancer	2C25.0	Approved	[12]
Marimastat	DM6V34C	Pancreatic cancer	2C10	Phase 3	[13]
BMS 275291	DMKSFPE	Kaposi sarcoma	2B57	Discontinued in Phase 3	[16]
BB-3644	DM7YRFE	Solid tumour/cancer	2A00-2F9Z	Terminated	[28]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[29]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[8]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[30]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[10]
3-Benzenesulfonyl-heptanoic acid hydroxyamide	DM7XDCF	Discovery agent	N.A.	Investigative	[31]
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	DMJSOTE	Discovery agent	N.A.	Investigative	[31]

Drug(s) Targeting Aggrecanase-1 (ADAMTS4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1607004-34-1	DMM2N4T	N. A.	N. A.	Patented	[32]
US9206139, 4	DM3NE8J	N. A.	N. A.	Patented	[32]
US9206139, 5	DMB4JS7	N. A.	N. A.	Patented	[32]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[33]
(R)-2-(biphenyl-4-sulfonylamino)-propionic acid	DM16JFS	Discovery agent	N.A.	Investigative	[33]

Drug(s) Targeting Matrix metalloproteinase-3 (MMP-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29130358-Compound-Figure10(2a)	DMFWXPS	N. A.	N. A.	Patented	[15]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[17]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[18]
PG-530742	DMELXBQ	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[34]
Batimastat	DM92VRP	Idiopathic pulmonary fibrosis	CB03.4	Preclinical	[35]
BB-1101	DM7GH5Z	Multiple sclerosis	8A40	Terminated	[36]
L-696418	DMV785R	N. A.	N. A.	Terminated	[37]
RO-319790	DML3NEU	Rheumatoid arthritis	FA20	Terminated	[38]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[27]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Aggrecanase (ADAMTS5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AGG-523	DMVMIBY	Osteoarthritis	FA00-FA05	Phase 1	[39]
PMID21536437C15c	DM2R94W	Discovery agent	N.A.	Investigative	[40]
CR-5259	DME5IJQ	Osteoarthritis	FA00-FA05	Investigative	[41]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aggrecanase (ADAMTS5)	TTXSU2Y	ATS5_HUMAN	Inhibitor	[1]
Aggrecanase-1 (ADAMTS4)	TTYG6BU	ATS4_HUMAN	Inhibitor	[1]
Matrix metalloproteinase-1 (MMP-1)	TTMX39J	MMP1_HUMAN	Inhibitor	[2]
Matrix metalloproteinase-2 (MMP-2)	TTLM12X	MMP2_HUMAN	Inhibitor	[2]
Matrix metalloproteinase-3 (MMP-3)	TTUZ2L5	MMP3_HUMAN	Inhibitor	[3]
Matrix metalloproteinase-7 (MMP-7)	TTMTWOS	MMP7_HUMAN	Inhibitor	[2]
Matrix metalloproteinase-8 (MMP-8)	TTGA1IV	MMP8_HUMAN	Inhibitor	[1]
Matrix metalloproteinase-9 (MMP-9)	TT6X50U	MMP9_HUMAN	Inhibitor	[1]

References

• [1] Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
• [2] A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
• [3] Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
• [4] Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
• [5] Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995).
• [6] New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908.
• [7] Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62.
• [8] Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
• [9] Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
• [10] Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
• [11] 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
• [12] AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
• [13] Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
• [14] Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
• [15] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [16] Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
• [17] Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
• [18] Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
• [19] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [20] Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
• [21] DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
• [22] National Cancer Institute Drug Dictionary (drug id 747683).
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [25] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
• [26] Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
• [27] Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
• [28] Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
• [29] Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
• [30] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
• [31] Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
• [32] Aggrecanase inhibitors. US9206139.
• [33] Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6.
• [34] Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
• [35] Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
• [36] Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
• [37] Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
• [38] The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
• [39] Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23.
• [40] Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3301-6.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1677).